Neurological disorder

Exclusively From AARP The Magazine: Adam Sandler Gets Philosophical About Aging, Actor Harry Hamlin Talks Trusting Your Gut, And '70s Icon Linda Ronstadt Reflects On Her Family and Health

Retrieved on: 
Monday, September 26, 2022

WASHINGTON, Sept. 26, 2022 /PRNewswire/ -- This fall, the October/November 2022 issue of AARP The Magazine (ATM) reflects on the maturity and changes, both in life and career, that come with age. Cover Feature and comedic genius Adam Sandler compares his mentality and confidence to his younger self just starting in the comedy scene, and how he now views the up-and-coming prodigies. Heartthrob Harry Hamlin talks following your intuition, even if that means saying no to the 'big one' – including a massive three-movie deal with Warner Bros. Award-winning singer Linda Ronstadt reveals excerpts from her upcoming memoir "Feels Like Home: A Song for the Sonoran Borderlands" while looking back on her childhood, her own style of parenting, and her battle with progressive supranuclear palsy. And Patti LaBelle gives advice for living honestly and happily off the stage.

Key Points: 
  • Heartthrob Harry Hamlin talks following your intuition, even if that means saying no to the 'big one' including a massive three-movie deal with Warner Bros.
  • And Patti LaBelle gives advice for living honestly and happily off the stage.
  • Actor Harry Hamlin talks following your gut, despite what might be offered your way, the secret to a 25+ year marriage, and his priorities when it comes to career and family.
  • To learn more, visit www.aarp.org , www.aarp.org/espanol or follow @AARP, @AARPenEspanol and @AARPadvocates, @AliadosAdelante on social media.

Duncan NRI at Texas Children's Hospital Accelerates Neurological Research and Therapies with Historic $10M Gift from The Blue Bird Circle

Retrieved on: 
Friday, September 23, 2022

HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.

Key Points: 
  • HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.
  • This historic donation is being made to commemorate the Blue Bird Circle's upcoming centennial anniversary and brings the organization's gifts to Texas Children's to over $25 million which will help advance life-changing neurological research at the Duncan NRI.
  • At Texas Children's Hospital Blue Bird Clinic, Blue Bird volunteers log more than 5,000 hours a year in administrative assistance the equivalent of three full-time employees.
  • The volunteers' time, effort, and donations help support The Blue Bird Circle Clinic for Pediatric Neurology at Texas Children's Hospital.

Wake Up Narcolepsy Physician Survey Shows Significant Challenges in Successful Diagnosis of Narcolepsy

Retrieved on: 
Thursday, September 22, 2022

WORCESTER, Mass., Sept. 22, 2022 /PRNewswire/ -- Wake Up Narcolepsy (WUN), a national leader for narcolepsy research and awareness, today announced the results of a survey of 100 physicians who treat narcolepsy in children and adolescents in the Greater Boston Area. These findings, which coincide with World Narcolepsy Day, highlight the challenges of identifying, managing and treating narcolepsy in this patient population.

Key Points: 
  • These findings, which coincide with World Narcolepsy Day , highlight the challenges of identifying, managing and treating narcolepsy in this patient population.
  • "These survey results are illuminating, as they highlight improved physician knowledge about narcolepsy compared to previously published data.
  • There are two main types of narcolepsy: narcolepsy with cataplexy (Type 1) and narcolepsy without cataplexy (Type 2).
  • Wake Up Narcolepsy (WUN) is a 501(c)(3) not-for-profit organization founded in 2008 to promote narcolepsy research and awareness.

Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer

Retrieved on: 
Wednesday, September 21, 2022

BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO). Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase. Dr. Bhatti's appointment follows the recent award of a £1.5M UK National Institute for Health and Care Research (NIHR) grant to Cumulus and its academic research partners, using the Cumulus platform to improve early dementia diagnosis. 

Key Points: 
  • Tapping AliveCor Senior Executive, Cumulus Signals Progression To A Global Healthcare Company; Dr. Bhatti To Lead Expansion of AI-Based Digital Biomarker Platform To Accelerate Patient Care and Drug Development in Neurology and Neuropsychiatry
    BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO).
  • Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase.
  • "Neurological disorders are a global health issue, and digital biomarkers which require integrated, multi-domain assessment technologies are key to supporting faster drug development, disease diagnosis, and therapeutic solutions," said Ruth McKernan, PhD, co-founder & executive chair, Cumulus.
  • The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.

Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer

Retrieved on: 
Wednesday, September 21, 2022

BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO). Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase. Dr. Bhatti's appointment follows the recent award of a £1.5M UK National Institute for Health and Care Research (NIHR) grant to Cumulus and its academic research partners, using the Cumulus platform to improve early dementia diagnosis.   

Key Points: 
  • Tapping AliveCor Senior Executive, Cumulus Signals Progression To A Global Healthcare Company; Dr. Bhatti To Lead Expansion of AI-Based Digital Biomarker Platform To Accelerate Patient Care and Drug Development in Neurology and Neuropsychiatry
    BELFAST, Northern Ireland, and BRIDGEWATER, N.J., Sept. 21, 2022 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the brain, today appointed Aman Bhatti, MD, as Chief Executive Officer (CEO).
  • Dr. Bhatti, a noted digital health executive with experience launching and scaling world-renowned consumer healthcare brands, joins Cumulus as the Company shifts toward healthcare and expands biopharma partnerships in its next growth phase.
  • "Neurological disorders are a global health issue, and digital biomarkers which require integrated, multi-domain assessment technologies are key to supporting faster drug development, disease diagnosis, and therapeutic solutions," said Ruth McKernan, PhD, co-founder & executive chair, Cumulus.
  • The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.

EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications

Retrieved on: 
Wednesday, September 21, 2022

The animal studies in the publication show that neflamapimod reduces Rab5 activity and reverses the neurodegenerative process in the basal forebrain.

Key Points: 
  • The animal studies in the publication show that neflamapimod reduces Rab5 activity and reverses the neurodegenerative process in the basal forebrain.
  • These combined pre-clinical and clinical results provide a foundation for a confirmatory, hypothesis-testing Phase 2b clinical study evaluating neflamapimod for DLB.
  • The data published today provide us confidence to progress neflamapimod into a confirmatory Phase 2b clinical trial in Dementia with Lewy Bodies.
  • et al., Preclinical and Randomized Clinical Evaluation of the p38 Kinase Inhibitor Neflamapimod for Basal Forebrain Cholinergic Degeneration, Nature Communications, 13, Article number: 5308 (2022).

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

Retrieved on: 
Tuesday, September 20, 2022

SELECT-HD ( NCT05032196 ) is an adaptive trial designed to rapidly optimize dose level and frequency based on early indicators of target engagement.

Key Points: 
  • SELECT-HD ( NCT05032196 ) is an adaptive trial designed to rapidly optimize dose level and frequency based on early indicators of target engagement.
  • Taken together, WVE-003 appears to have a unique profile with the potential to overcome prior therapeutic challenges in this field.
  • The availability of this assay has potential to significantly increase our understanding of how best to treat this challenging disease.
  • Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

Amprion Exhibits at MDS International Congress of Parkinson's Disease and Movement Disorders in Madrid and Presents Scientific Insights On SYNTap® Test at Prion2022

Retrieved on: 
Thursday, September 15, 2022

SAN FRANCISCO, Sept. 15, 2022 /PRNewswire-PRWeb/ -- Amprion, a leader in diagnostics for neurodegenerative diseases, invites researchers and practitioners attending MDS to visit Amprion at booth #212. We look forward to discussing how the SYNTap® Biomarker Test addresses the unmet medical need for a validated clinical test to diagnose Parkinson's disease (PD) and differentiate PD from atypical Parkinson's at early stages. Accurate and early diagnosis helps accelerate personalized treatment and therapeutic innovations.

Key Points: 
  • Amprion will host a Meet the Expert session with Neurologist Brit Mollenhauer, MD, in which attendees can discuss scientific insights on how the SYNTap Test performs in a clinical setting.
  • In addition to the exhibit at MDS, Amprion Chief Scientific Officer Claudio Soto, Ph.D., will speak at International Conference Prion2022, September 13-16 in Gttingen, Germany.
  • SAN FRANCISCO, Sept. 15, 2022 /PRNewswire-PRWeb/ -- Amprion, a leader in diagnostics for neurodegenerative diseases, invites researchers and practitioners attending MDS to visit Amprion at booth #212.
  • Dr. Lebovitz will attend MDS, International Congress of Parkinson's Disease and Movement Disorders in Madrid, September 15-18.

Neurovation Labs Announces Issuance of Second U.S. Patent Covering Compositions and Methods for Detecting PTSD Biomarker

Retrieved on: 
Wednesday, September 14, 2022

The patent, entitled "Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated Post-Traumatic Stress Disorder and Other Neurological Disorders," is directed to novel radiotracer compositions as well as methods for detecting GluA1 and GluA1-containing central nervous system receptors.

Key Points: 
  • The patent, entitled "Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated Post-Traumatic Stress Disorder and Other Neurological Disorders," is directed to novel radiotracer compositions as well as methods for detecting GluA1 and GluA1-containing central nervous system receptors.
  • "The compounds protected by this patent are part of a series of radiotracers that Neurovation Labs is developing to enable objective diagnosis of brain disorders and to better evaluate the mechanisms underlying PTSD and other brain traumas.
  • This patent is owned solely by Neurovation Labs and is the second issuance from a broader intellectual property portfolio stemming from the company's research and development.
  • Neurovation Labs is a biotechnology company revolutionizing the way psychiatric disorders are diagnosed and treated, with an initial focus on PTSD.

hC Bioscience Appoints Brad Margus to its Board of Directors

Retrieved on: 
Tuesday, September 13, 2022

CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- hC Bioscience, Inc. , a company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, today announced the appointment of industry veteran Brad Margus to its board of directors.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- hC Bioscience, Inc. , a company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, today announced the appointment of industry veteran Brad Margus to its board of directors.
  • We are excited to welcome Brad to the company during this pivotal time of growth, said Leslie Williams, co-founder, director and chief executive officer of hC Bioscience.
  • Mr. Margus brings more than 30 years of company building and corporate leadership experience to hC Bioscience.
  • hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting protein dysfunction.